[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Astrazeneca Plc (AZN)

Astrazeneca Plc (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 248,300,384
  • Shares Outstanding, K 1,550,908
  • Annual Sales, $ 58,739 M
  • Annual Income, $ 10,225 M
  • EBIT $ 13,971 M
  • EBITDA $ 19,704 M
  • 60-Month Beta 0.26
  • Price/Sales 4.14
  • Price/Cash Flow 12.14
  • Price/Book 4.83

Options Overview Details

View History
  • Implied Volatility 27.20% (+27.20%)
  • Historical Volatility 37.56%
  • IV Percentile 50%
  • IV Rank 51.29%
  • IV High 34.22% on 02/05/26
  • IV Low 19.81% on 08/22/25
  • Expected Move (DTE 2) 2.89 (1.75%)
  • Put/Call Vol Ratio 0.24
  • Today's Volume 4,756
  • Volume Avg (30-Day) 4,883
  • Put/Call OI Ratio 0.59
  • Today's Open Interest 109,536
  • Open Int (30-Day) 81,710
  • Expected Range 162.37 to 168.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $2.64
  • Number of Estimates 3
  • High Estimate $2.69
  • Low Estimate $2.60
  • Prior Year $2.38
  • Growth Rate Est. (year over year) +10.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
153.41 +7.81%
on 08/03/26
175.04 -5.50%
on 07/29/26
-3.50 (-2.07%)
since 07/17/26
3-Month
153.41 +7.81%
on 08/03/26
196.41 -15.79%
on 07/02/26
-19.24 (-10.42%)
since 05/19/26
52-Week
145.79 +13.45%
on 09/25/25
212.71 -22.24%
on 02/18/26
+6.32 (+3.97%)
since 08/19/25

Most Recent Stories

More News
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

AstraZeneca and Daiichi Sankyo’s ENHERTU is the first and only HER2-directed medicine to improve progression-free survival over global standard of...

AZN : 165.74 (+3.52%)
AZN.LN : 12,049.998 (+2.07%)
TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO

First global Phase III trial to show significant progression-free and overall survival benefits in this setting SAFFRON trial results reinforce TAGRISSO...

AZN : 165.74 (+3.52%)
AZN.LN : 12,049.998 (+2.07%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

NEW YORK , Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NYSE: AZN). Such investors are advised to...

AZN : 165.74 (+3.52%)
MRNA Stock Gets a Shot in the Arm as FDA Approves Moderna Flu Vaccine

Moderna has secured FDA approval for its flu vaccine mFLUSIVA. But does that warrant buying MRNA shares today? Let’s find out!

AZN : 165.74 (+3.52%)
MRNA : 168.60 (+167.79%)
RHHBY : 58.1950 (+4.81%)
PFE : 28.22 (+3.56%)
SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

BOSTON and ROLLE, Switzerland , Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS  (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics...

SOPH : 8.18 (+7.35%)
AZN : 165.74 (+3.52%)
The $400 Billion Reason Bristol-Myers Squibb (BMY) Stock Is Up Today

Bristol-Myers stock extends gains on reports of a potential merger with AstraZeneca. But caution is warranted in chasing the momentum in BMY shares today.

AZN : 165.74 (+3.52%)
BMY : 67.64 (+2.41%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

NEW YORK , July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NYSE: AZN).  Such investors are advised...

AZN : 165.74 (+3.52%)
Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers

Results provide opportunity to expand CLDN18.2 positivity to ≥25% expression, representing approximately 60% of patients in this setting CLARITY-Gastric01...

AZN : 165.74 (+3.52%)
AZN.LN : 12,049.998 (+2.07%)
AstraZeneca results: H1 and Q2 2026

Growth momentum continues. On track to deliver ambition of $80 billion in Total Revenue in 2030

AZN : 165.74 (+3.52%)
AZN.LN : 12,049.998 (+2.07%)
FOMC Out Next Week with Interest Rate Decision

Monday U.S. Economic Lookahead Durable-goods orders (June) Featured Earnings AstraZeneca ...

KLAC : 187.70 (-3.64%)
META : 547.21 (+0.65%)
AAPL : 315.47 (+1.75%)
KO : 90.42 (+1.80%)
CVX : 205.42 (+0.72%)
WELL : 235.67 (+0.10%)
ABBV : 266.63 (+2.98%)
MSFT : 483.30 (+0.35%)
MA : 575.17 (+0.15%)
AZN : 165.74 (+3.52%)
V : 366.87 (+0.72%)
XOM : 164.89 (-0.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition...

See More

Key Turning Points

3rd Resistance Point 162.49
2nd Resistance Point 161.57
1st Resistance Point 160.83
Last Price 165.74
1st Support Level 159.17
2nd Support Level 158.25
3rd Support Level 157.51

See More

52-Week High 212.71
Fibonacci 61.8% 187.15
Fibonacci 50% 179.25
Fibonacci 38.2% 171.35
Last Price 165.74
52-Week Low 145.79

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.